The use of selective Janus kinase inhibitor upadacitinib in a patient with psoriatic arthritis (clinical observation)
We describe a patient with psoriatic arthritis (PSA) and palmoplantar psoriasis, resistant to standard therapy, who observed a significant decrease in disease activity on the background of upadacitinib at a dose of 15 mg/day. Remission was achieved by the 3rd month of treatment. No adverse phenomena...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2025-04-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1746 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|